Articles published by Calidi Biotherapeutics, Inc.

Calidi to Effect Reverse Stock Split

July 05, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

June 27, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

June 11, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

June 10, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

June 03, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

May 31, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

May 14, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

May 01, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

April 23, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

April 19, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

April 16, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

April 09, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

March 15, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

March 11, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

January 08, 2024

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

December 13, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

December 12, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

November 20, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

November 14, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)

November 03, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

November 01, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer

October 30, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023

October 10, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers CLDI

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

September 13, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference

September 12, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients

July 18, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

June 23, 2023

From Calidi Biotherapeutics, Inc.

Via Business Wire

Tickers FLAG

Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

December 13, 2022

From Calidi Biotherapeutics, Inc.

Via Business Wire

Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit

December 06, 2022

From Calidi Biotherapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.